Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|February 27, 2026
Building Fair and Trustworthy Biomedical AI: A Tool for Identifying Key Decision PointsNicole Foti, Janet K Shim, Caitlin McMahon, et al.
Journal of Religion and Health|September 4, 2009
Introducing spirituality into psychiatric careMarc Galanter, Helen Dermatis, Nancy Talbot, et al.
Journal of Autism and Developmental Disorders|September 24, 2013
Social smiling and its components in high-risk infant siblings without later ASD symptomatologyCaitlin McMahon Nichols, Lisa V Ibañez, Jennifer H Foss-Feig, et al.
Substance Abuse|February 9, 2011
Alcoholics Anonymous and the Minnesota Model of treatment in IcelandDaniel McMenamin, Matthew Warren, Thornorarinn Tyrfingsson, et al.
Case Reports in Oncology|June 14, 2016
A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer PatientSiraj M Ali, Jessica Watson, Kai Wang, et al.
Social Science & Medicine (1982)|June 21, 2022
Strategies of inclusion: The tradeoffs of pursuing "baked in" diversity through place-based recruitmentJanet K Shim, Michael Bentz, Emily Vasquez, et al.
The American Journal of Surgical Pathology|February 28, 2015
A Novel SDHA-deficient Renal Cell Carcinoma Revealed by Comprehensive Genomic ProfilingEvgeny Yakirevich, Siraj M Ali, Anthony Mega, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2015
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastasesVivek Subbiah, Jenny Berry, Michael Roxas, et al.
Oncotargets and Therapy|December 15, 2015
A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapyCasey B Williams, Caitlin McMahon, Siraj M Ali, et al.
Journal of Hematology & Oncology|June 12, 2015
STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusionVivek Subbiah, Caitlin McMahon, Shreyaskumar Patel, et al.
Pageof 2